Article Text

Download PDFPDF

PO.1.5 Scoring personalized molecular portraits identify systemic lupus erythematosus subtypesand predict transcriptional drug responses, symptomatology and disease progression
  1. D Toro Dominguez1,
  2. M Martínez Bueno1,
  3. R López Domínguez1,2,
  4. J Martorell Marugan1,
  5. E Carnero Montoro1,
  6. G Barturen1,
  7. D Goldman3,
  8. M Petri3,
  9. P Carmona Saez1,2 and
  10. M Alarcón-Riquelme1,4
  1. 1Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government,(GENYO), Granada, Spain
  2. 2University of Granada, Spain
  3. 3Johns Hopkins University School of Medicine, Baltimore, USA
  4. 4Karolinska Institute, Solne, Sweden


Purpose Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, such that personalized medicine offers major promise. With this work we intended to advance in that direction by developing My PROSLE, an omics-based workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions.

Methods Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 4300 lupus and 750 healthy samples were used to analyze the association between dysregulation scores, clinical manifestations, prognosis, flare and remission events and transcriptional drug response to Tabalumab. Machine learning-based classification models were built to predict around 90 different clinical parameters based on personalized dysregulation scores.

Results My PROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into 9 main lupus signatures (Example in figure 1, the combination of which revealed highly differentiated pathological mechanisms. We show that dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the potential presence of long-term remission and drug response. Therefore, My PROSLE could be used to accurately predict these clinical outcomes.

Conclusions My PROSLE ( allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.